SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Russian Bear who wrote (4561)4/6/1998 11:29:00 PM
From: Flagrante Delictu  Read Replies (1) of 9719
 
RB, Michasl Murphy opines that since the FDA has a late May deadline to reach a decision, the Apr 9 meeting was originally set up to allow the review panel meeting then, to hand up an opinion in a reasonable time. He thinks the cancellation avoids the need for the FDA to have to hear a probable panel rejection,thereby enabling an unopposed positive FDA decision, since the panel will no longer have sufficient time to meet & hand up their objection. To be safe, he also allows for the FDA to extend the timeframe, but gives it a low probability. Be forewarned, this is my interpretation of his thesis. I have no position currently in the stock.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News